You are here: » News » Newsdetails: Uncertainty for Gene Therapy


Uncertainty for Gene Therapy

September 14, 2017

Uncertainty for gene therapy following withdrawal from market of Europe’s first gene therapeutic

Dutch biotechnology company uniQure B.V., (NASDAQ:QURE), Amsterdam, The Netherlands, has announced that it will not pursue the renewal of its Glybera (alipogene tiparvovec) marketing authorization in Europe, scheduled to expire on October 25, 2017.